Follow
'The review correctly identifies a multitude of factors that have led to a decline in clinical trials, including the pressures on the Medicines and Healthcare products Regulatory Agency, which has a reduced capacity and increased workload post-pandemic and post-Brexit, and other aspects of the national and local trial approvals systems, which have undermined the competitiveness of the UK clinical research environment.'
